ClinicalTrials.gg
RecruitingNCT06656065Updated Nov 21, 2025

IMR-Heart Trasplant Study

An observational study in Heart Transplant Rejection and Microvascular Resistance, sponsored by Hospital Miguel Servet. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Hospital Miguel Servet · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Acute allograft rejection (AAR) is an important cause of morbi-mortality in heart transplant (HT) patients, particularly during the first year. Endomyocardial biopsy (EMB) is the "gold standard" to guide post- heart transplantation treatment. However, it is associated with complications that can be potentially serious. The index of microvascular resistance (IMR) is a specific physiological parameter used to assess microvascular function. Invasive coronary assessment has been shown to be both feasible and safe. Detection of coronary microvascular dysfunction (MCD) by IMR may help to identify high risk HT patients. In fact, an increased IMR measured early after HT has been associated with AAR, higher all-cause mortality and adverse cardiac events. A high IMR value early after HT may identify patients at higher risk who require increased surveillance or adjustments in immunosuppressive therapy. Conversely, a low IMR value may support reducing the number of EMBs. Our aim is to evaluate IMR in heart transplant patients within the first year. Changes in management after knowing IMR values and prognostic implications of IMR in a long term follow up will also be assessed.

Read the detailed description

The IMR-HT study is a multicenter, prospective observational study that will include post-HT stable patients undergoing coronary physiological assessment in the first three months and one year.

Assessment of IMR, coronary flow reserve (CFR) and fractional flow reserve (FFR) will be performed using the standard thermodilution technique. The left anterior descending coronary artery will be evaluated in all patients. Circumflex or right coronary artery could be additionally evaluated at operator's discretion. An intracoronary pressure and temperature sensor-tipped guidewire (Pressure Wire TM X guide- wire 0.014', Abbott, IL, USA) will be used to perform the measurements. The tip pressure sensor will be advanced into the mid-to-distal portion of the evaluated vessel. Baseline aortic pressure (Pa) and distal intracoronary pressure (Pd) will be obtained to calculate the resting index Pd/Pa. To measure the mean transit time (Tmn) under basal conditions, intracoronary administration of 3 mL of room-temperature saline will be manually injected three times in succession (3 mL/s). Then maximal hyperemia will be induced using adenosine iv (140 to 180 mg/kg/min) and three additional intracoronary room temperature saline boluses of 3 ml will be administered to determine the mean transit time at hyperemia (Tmnh). Finally, fractional flow reserve (FFR), coronary flow reserve (CFR) and IMR will be calculated using the software Coroventis Coroflow (Coroventis Abbott, Uppsala, Sweden).

Changes in HT patient management (number of EMBs, immunosuppressive therapy modifications) after knowing IMR values will also be assessed.

Based on previously published clinical data on IMR in heart transplant patients, a post-HT management algorithm is proposed:

  • IMR \< 15: The frequency of biopsies could be reduced or maintained as per protocol. No changes to immunosuppressive therapy would be required.
  • IMR ≥ 15: Biopsies would be performed at the standard frequency according to protocol. Immunosuppressive therapy could be intensified or maintained the same.

Of note, given the observational characteristics of the study, clinical management decisions will be made at the discretion of the treating physician, taking into account the patient's clinical condition and other complementary tests.

Both groups (IMR\<15 vs IMR≥15) will be compared in terms of cardiac events occurrence.

Clinical conditions, laboratory findings and clinical events will be assessed at one month and one year. Follow up will be extended for up to five years. Data will be included in an online database specifically designed for the study on platform REDCap (Research Electronic Data Capture).

A number will be assigned to each patient; their identity will not be disclosed in any case. All shared information will be anonymized. The principal investigator at each center will be responsible for keeping the data anonymized.Data will be processed in accordance with the protection legislation in force (Spanish Personal Data Protection and Guarantee of Digital Rights Act 3/2018, and Regulation (EU) 2016/679).

Our aim will be to assess IMR values in heart transplant patients within one year and evaluate changes in management after knowing of IMR values. We believe it is important to move forward in AAR surveillance and reduce the number of endomyocardial biopsies. In addition to assessing their diagnostic capabilities, IMR should also be assessed based on clinical outcomes. Therefore, we are convinced the results of this trial will be very important for our HT patient population.

02

Conditions studied

  • Heart Transplant Rejection
  • Microvascular Resistance

Keywords

  • Heart Trasplant
  • Acute cellular rejection
  • IMR
  • Endomyocardial biopsy
03

In context

Lead sponsor

Hospital Miguel Servet is the lead sponsor of 25 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Heart trasplant patients that have signed informed consent and meet all inclusion and exclusion criteria for undergoing IMR assessment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heart transplant patients >18 years.
  • Patients who have received and signed .

Exclusion criteria

Exclusion Criteria:

  • Patients with hemodynamic instability after HT, including cardiogenic shock or severe coagulopathy.
  • Patients with acute cellular rejection before intracoronary physiological assessment.
  • Patients with bronchial asthma or bronchopathy with a positive bronchodilation test, which contraindicates the use of adenosine.
  • Patients with epicardial coronary lesions with a resting physiological index ≤0.89 or ≤0.80 at hyperemia.
  • Patients unlikely to cooperate or with inability or unwillingness to give .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • IMR≥15

    Heart trasplant patient with an index of microvascular resistance ≥ 15 measured in the first three months in the physiological study.

  • IMR<15

    Heart trasplant patient with an index of microvascular resistance\<15 measured in the first three months in the physiological study.

06

What researchers measure

Primary outcomes

  1. IMR values in the first three months and one year after heart transplant

    IMR measured by the invasive thermodilution technique. IMR is defined as the distal coronary pressure divided by the inverse of the hyperemic mean transit time and is expressed in units of mmHg.s.

    Time frame: One year

Secondary outcomes

  1. IMR variation between first three months after HT and one year

    Comparison between the values of index of microvascular resistance (IMR) measured by bolus thermodilution technique between the first and 3rd month after HT and one year in the invasive physiological study. IMR may be expressed as mmHg·s.

    Time frame: One year

  2. Acute cellular rejection

    A ≥2R degree according to the 2010 ISHLT system. Two or more focal infiltration points associated with myocyte injury in EMB. Diffuse infiltration with multi-focal myocyte injury with/without oedema, hemorrhage or vasculitis.

    Time frame: One year

  3. Cardiac allograft vasculopathy

    Accelerated fibroproliferative process characterized by diffuse, concentric and longitudinal thickening of the intima of the vascular tree of the graft, affecting everything from the major epicardial arteries to the coronary microvasculature.

    Time frame: Five years

  4. Cardiovascular mortality

    Caused by cardiovascular disease or unknown death

    Time frame: Five years

  5. Heart failure

    Diastolic or systolic heart failure after heart transplant

    Time frame: Five years

  6. Inmunosupressive therapy

    Changes in any of the inmunosuppresive agents pre-established in each center heart transplant protocol

    Time frame: Five years

  7. EMB performed in each center within the first year

    The number of biopsies performed by each center, after knowing IMR baseline values.

    Time frame: One year

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Lee JM, Choi KH, Choi JO, Shin D, Park Y, Kim J, Lee SH, Kim D, Yang JH, Cho YH, Sung K, Choi JY, Park M, Kim JS, Park TK, Song YB, Hahn JY, Choi SH, Gwon HC, Oh JK, Jeon ES. Coronary Microcirculatory Dysfunction and Acute Cellular Rejection After Heart Transplantation. Circulation. 2021 Nov 2;144(18):1459-1472. doi: 10.1161/CIRCULATIONAHA.121.056158. Epub 2021 Sep 3. PubMed 34474597 ↗
  • Okada K, Honda Y, Luikart H, Yock PG, Fitzgerald PJ, Yeung AC, Valantine HA, Khush KK, Fearon WF. Early invasive assessment of the coronary microcirculation predicts subsequent acute rejection after heart transplantation. Int J Cardiol. 2019 Sep 1;290:27-32. doi: 10.1016/j.ijcard.2019.04.018. Epub 2019 Apr 8. PubMed 30987835 ↗
  • Ahn JM, Zimmermann FM, Gullestad L, Angeras O, Karason K, Russell K, Lunde K, Okada K, Luikart H, Khush KK, Honda Y, Pijls NHJ, Lee SE, Kim JJ, Park SJ, Solberg OG, Fearon WF. Microcirculatory Resistance Predicts Allograft Rejection and Cardiac Events After Heart Transplantation. J Am Coll Cardiol. 2021 Dec 14;78(24):2425-2435. doi: 10.1016/j.jacc.2021.10.009. PubMed 34886963 ↗
  • Hiemann NE, Wellnhofer E, Knosalla C, Lehmkuhl HB, Stein J, Hetzer R, Meyer R. Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. Circulation. 2007 Sep 11;116(11):1274-82. doi: 10.1161/CIRCULATIONAHA.106.647149. Epub 2007 Aug 20. PubMed 17709643 ↗
  • Saraiva F, Matos V, Goncalves L, Antunes M, Providencia LA. Complications of endomyocardial biopsy in heart transplant patients: a retrospective study of 2117 consecutive procedures. Transplant Proc. 2011 Jun;43(5):1908-12. doi: 10.1016/j.transproceed.2011.03.010. PubMed 21693299 ↗
  • Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D Jr, Hsich E, Meiser B, Potena L, Robinson A, Rossano JW, Sadavarte A, Singh TP, Zuckermann A, Stehlik J; International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019 Oct;38(10):1056-1066. doi: 10.1016/j.healun.2019.08.004. Epub 2019 Aug 10. No abstract available. PubMed 31548031 ↗
  • Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O'Connell J, Rogers J, Ross H, Russell S, Vanhaecke J; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010 Aug;29(8):914-56. doi: 10.1016/j.healun.2010.05.034. No abstract available. PubMed 20643330 ↗
  • Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb S, Levvey BJ, Meiser B, Rossano JW, Yusen RD, Stehlik J. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015 Oct;34(10):1244-54. doi: 10.1016/j.healun.2015.08.003. Epub 2015 Aug 28. No abstract available. PubMed 26454738 ↗

Individual participant data

Plan to share: Yes — All collected IPD

Supporting information: Study protocol, Statistical analysis plan

Time frame: October 2024

Access criteria: All researches/physicians involved in this investigational field

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for May 2028, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 24, 2024
StartActual
May 23, 2023
Primary completionEst.
May 23, 2028
CompletionEst.
Oct 14, 2028
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06656065
Lead sponsor
Hospital Miguel Servet
Collaborators
Central University Hospital of Asturias, Hospital Universitario La Fe, University Hospital Virgen de la Arrixaca, Murcia, University Hospital 12 Octubre, Madrid, Hospital Universitario Reina Sofia de Cordoba, Hospital Universitari de Bellvitge, Hospitales Universitarios Virgen del Rocío
Responsible party
Georgina Fuertes Ferre (Dr. Fuertes, Hospital Miguel Servet) — Principal investigator
First posted
Oct 24, 2024
Start date
May 23, 2023
Primary completion
May 23, 2028 (estimated)
Completion
Oct 14, 2028 (estimated)
Last update
Nov 21, 2025

Study contacts

Georgina Fuertes, MD PHD
Contact
georginaff@hotmail.com
0034 976765500 ext. 5160
Ainhoa Perez Guerrero, MD
Contact
ainhoaperezguerrero@gmail.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion